Zomedica Corp. Reports Strong Financial Performance in Q2 2025

Zomedica Corp., a veterinary biopharmaceutical company listed on the OTC Bulletin Board, has announced its financial results for the second quarter of 2025, showcasing a robust 14% increase in revenue, reaching $7 million. This growth marks the 18th consecutive quarter of record year-over-year revenue, highlighting the company’s consistent performance in the health care sector, specifically within the pharmaceuticals industry.

The company, which operates primarily in North America, reported impressive 67% gross margins, further emphasizing its strong financial health. Additionally, Zomedica maintains a substantial liquidity position with $59 million available to support its growth initiatives. This financial stability is crucial as the company continues to focus on drug discovery and development for pet health, serving veterinarians with innovative diagnostic and therapeutic products for equine and companion animals.

Larry Heaton, Chief Executive Officer of Zomedica, expressed satisfaction with the company’s performance, attributing the success to strategic initiatives and a strong market presence. “We are very pleased with the 14% growth attained in the second quarter as we posted record year-over-year revenue for the 18th straight quarter,” Heaton stated.

Upcoming Investor Conference

In addition to its financial achievements, Zomedica is set to present at the OTCQB Venture Virtual Investor Conference on August 7th, 2025. The company has extended an invitation to individual and institutional investors, as well as advisors and analysts, to attend the event online. This conference provides an opportunity for stakeholders to gain insights into Zomedica’s strategic vision and future plans.

The company’s market capitalization stands at $51.97 million, with a close price of $0.038 as of August 4, 2025. Despite a negative price-to-earnings ratio of -0.363, Zomedica’s consistent revenue growth and strong liquidity position suggest a promising outlook for the company’s future endeavors.

For more information, stakeholders can visit Zomedica’s website at www.zomedica.com .